SEC 2	Form 4
-------	--------

FORM 4	l
--------	---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

3235-0287

OMB Number:

Form filed by One Reporting Person

Form filed by More than One Reporting

X

Person

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT
obligations may continue. See Instruction 1(b).	Filed p

OF CHANGES IN BENEFICIAL OWNERSHIP

Section 16	s. Form 4 or Form 5 may continue. See 1(b).	Fi	led pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940		Estimated average burden hours per response:	0.5
SNODGE (Last) C/O VISTA	Address of Reporting Person <u>RASS H. RALPH</u> (First) .GEN THERAPEUTICS RTON AVENUE	(Middle)	2. Issuer Name and Ticker or Trading Symbol <u>VistaGen Therapeutics, Inc.</u> [VTGN] 3. Date of Earliest Transaction (Month/Day/Year) 04/26/2017	(Check all applicabl X Director X Officer (giv below)	10% Owner	
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Join	t/Group Filing (Check Applicable	

SOUTH SAN FRANCISCO	CA	94080
(City)	(State)	(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	Date (Month/Day/Year)	if any 🤺						Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	,) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Stock Option (Right to Buy)	\$1.96	04/26/2017		A		125,000		(1)	04/26/2027	Common Stock	125,000	\$0	125,000	D	

Explanation of Responses:

1. One third (1/3rd) of the total shares shall vest one (1) year following the date of grant and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested three (3) years from the date of grant.

/s/ Jerrold D. Dotson, Attorney-04/28/2017

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.